A Study to Evaluate the Feasibility of HER2-Directed Targeted Therapy in Patients With Heavily Pretreated HER2-Negative Metastatic Breast Cancer With Elevated Serum Levels of The Soluble HER2 Extracellular Domain and/or HER2-Overexpressing Circulating Tumor Cells

Trial Profile

A Study to Evaluate the Feasibility of HER2-Directed Targeted Therapy in Patients With Heavily Pretreated HER2-Negative Metastatic Breast Cancer With Elevated Serum Levels of The Soluble HER2 Extracellular Domain and/or HER2-Overexpressing Circulating Tumor Cells

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2016

At a glance

  • Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Feb 2016 New trial record
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top